ResearcherSichuan UniversityActive in the last 2 years

Wanting Hou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0006-1215-1043; OpenAlex author ID A5056574442. Sources: OpenAlex.

Their work

Papers: 5 (first author 2, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 21

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 5

Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcinoma: a multicenter, single-arm, phase II … Co-author DOI 10.1158/1078-0432.ccr-26-1824 ↗
Lived experiences of patients with advanced pancreatic cancer on patient-reported outcomes (PROs) management: a qualitative phenomenological study in Southwest… First author DOI 10.1136/bmjopen-2024-084259 ↗
RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line treatment for metastatic pancreatic adenocar… Co-author DOI 10.21203/rs.3.rs-7291840/v1 ↗
Panoramic tumor microenvironment in pancreatic ductal adenocarcinoma. First author DOI 10.1007/s13402-024-00970-6 ↗
Nanoparticle-Based Therapeutic Strategies for Enhanced Pancreatic Ductal Adenocarcinoma Immunotherapy. Co-author DOI 10.3390/pharmaceutics14102033 ↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yi Cheng · 3 shared papers, 2025–2026 · strength 0.64
- Paper Lived experiences of patients with advanced pancreatic cancer on patient-reported outcomes (PROs) management: a qualita… DOI 10.1136/bmjopen-2024-084259 ↗
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824 ↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Chengjian Zhao · 2 shared papers, 2024–2025 · strength 0.42
- Paper Panoramic tumor microenvironment in pancreatic ductal adenocarcinoma. DOI 10.1007/s13402-024-00970-6 ↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Xiaoying Li · 2 shared papers, 2024–2025 · strength 0.42
- Paper Panoramic tumor microenvironment in pancreatic ductal adenocarcinoma. DOI 10.1007/s13402-024-00970-6 ↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Zixing Huang · 2 shared papers, 2025–2026 · strength 0.36
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824 ↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Chen Chang · 2 shared papers, 2025–2026 · strength 0.36
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824 ↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Junjie Xiong · 2 shared papers, 2025–2026 · strength 0.36
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824 ↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Ke Cheng · 2 shared papers, 2025–2026 · strength 0.36
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824 ↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Dan Cao · 2 shared papers, 2025–2026 · strength 0.36
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824 ↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Xiaorui Zhu · 2 shared papers, 2025–2026 · strength 0.36
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824 ↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Qingqing Leng · 2 shared papers, 2025–2026 · strength 0.36
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824 ↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Chenyan Zhang · 2 shared papers, 2025–2026 · strength 0.36
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824 ↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Ping Chen · 1 shared paper, 2025 · strength 0.28
- Paper Lived experiences of patients with advanced pancreatic cancer on patient-reported outcomes (PROs) management: a qualita… DOI 10.1136/bmjopen-2024-084259 ↗
Hong Zhu · 1 shared paper, 2022 · strength 0.26
- Paper Nanoparticle-Based Therapeutic Strategies for Enhanced Pancreatic Ductal Adenocarcinoma Immunotherapy. DOI 10.3390/pharmaceutics14102033 ↗
Dan Cao · 1 shared paper, 2024 · strength 0.26
- Paper Panoramic tumor microenvironment in pancreatic ductal adenocarcinoma. DOI 10.1007/s13402-024-00970-6 ↗
Yi Zhang · 1 shared paper, 2026 · strength 0.19
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824 ↗
Bole Tian · 1 shared paper, 2026 · strength 0.19
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824 ↗
Yi Zhang · 1 shared paper, 2025 · strength 0.16
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Huanji Xu · 1 shared paper, 2025 · strength 0.16
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Bole Tian · 1 shared paper, 2025 · strength 0.16
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Rui Wang · 1 shared paper, 2025 · strength 0.16
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Bo Chen · 1 shared paper, 2025 · strength 0.16
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.